Global High Content Screening (HCS) Market 2015-2019
High-content screening (HCS) technology involves imaging-based multi-parametric analysis at the single-cell level. This technology was initially developed to complement biological high throughput screening in drug discovery. HCS analyses phenotypic changes in cellular samples.
Technavio's analysts forecast the global HCS market to grow at a CAGR of 11.53% over the period 2014-2019.
Covered in this Report
The report includes the present scenario and the growth prospects of the global HCS market for the period 2015-2019. The market can be segmented into three customer segments: Pharmaceutical and biotechnology companies, academia and research institutes, and contract research organizations.Technavio's report, Global HCS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global HCS market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
Technavio Announces the Publication of its Research Report – Global High-Content Screening (HCS) Market 2015-2019
Technavio recognizes the following companies as the key players in the Global High-Content Screening (HCS) Market: Becton, Dickinson and Company, GE Healthcare, Danaher, PerkinElmer and Thermo Fisher Scientific
Other Prominent Vendors in the market are: Blue Sky Bioservices, Cell Signaling Technology, Charles River Laboratories International, Cytoo, EMD Millipore, Evotec, Fluofarma, Genedata, Imagen Biotech, Thorlabs, Tecan, Vala Sciences, Wako Automation and Yokogawa
Commenting on the report, an analyst from Technavio’s team said: “Sophisticated technologies and tools such as HCS systems enable rapid, large-scale, quantitative assessments of molecular and cellular biology procedures. Important discoveries in the biomedical field through the use of HCS have already been implemented in clinical diagnostics, especially in oncology and neurology. The identification of oncogenic variants via genomic testing technologies and their response to specific drugs are extensively used to develop personalized medicine. Both drug-target verification and pathway detection in neuroscience research help along drug discovery for neurodegenerative diseases. These advances enable the analysis and generation of big data in applied life sciences research and information transfer during drug discovery and development.”
According to the report, novel HCS instruments that can advance the fields of cell biology, genetics, and molecular biology and accelerate the drug discovery process have been developed. This is possible due to the availability of automated HCS with increased throughput, ease of use, and accuracy. Two examples of such HCS include the High Volume Data Management and Analysis system by PerkinElmer for the phenotypic screening of biological samples and the ImageXpress 5000A imaging instrument from Molecular Devices, which comes with a custom-built CCD camera. Yet another example is the KineticScan system by Cellomics, which is designed for measuring the kinetic properties of cells.
Further, the report states that issues related to managing large amounts of data restrict market growth.
Becton, Dickinson and Company, GE Healthcare, Danaher, PerkinElmer, Thermo Fisher Scientific, Blue Sky Bioservices, Cell Signaling Technology, Charles River Laboratories International, Cytoo, EMD Millipore, Evotec, Fluofarma, Genedata, Imagen Biotech, Thorlabs, Tecan, Vala Sciences, Wako Automation, Yokogawa